Idarubicin is an anthracycline antineoplastic agent used to treat acute myeloid leukemia (AML) in adults. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Mechanism
- Curator reviewed
Idarubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Idarubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.
- Primary indication
- For the treatment of acute myeloid leukemia (AML) in adults.Curator reviewed · 2 structured indications
- Formula / weight
- C26H27NO9 · 497.4939 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1990
- Also known as
- 4-Demethoxydaunorubicin
- Code names
- IMI-30 · SC-33428
- Brand names
Resolves to
XDXDZDZNSLXDNA-TZNDIEGXSA-NSMILESC[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]1C[C@@](O)(CC2=C1C(O)=C1C(=O)C3=CC=CC=C3C(=O)C1=C2O)C(C)=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Idarubicin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account